QuidelOrtho forecasts $2.7B-$2.75B 2026 revenue while targeting $100M-$120M free cash flow amid China pricing uncertainty
QuidelOrtho Corporation Common Stock · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · Now $13.27
-9.1% in 3d after detection
Post-detection moves
1h
—
1d
-1.7%
3d
-9.1%
7d
-5.8%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS